An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis

Janssen Pharmaceutica473 enrolled

Overview

The purpose of this study is to evaluate the efficacy, safety and effects on Quality of Life (QOL) of tramadol/paracetamol (APAP) as an add-on therapy (medication taken in addition to another medication) in Filipino participants with chronic (lasting a long time) osteoarthritis (disorder, which is seen mostly in older persons, in which the joints become painful and stiff).

This is an open-label (all people know the identity of the intervention), randomized (study drug assigned by chance), controlled study to evaluate the efficacy, safety and effects on QOL of tramadol/APAP as an add-on therapy in Filipino participants suffering from chronic pain because of chronic osteoarthritis. Participants will be randomly assigned to 2 groups: tramadol/APAP group and non tramadol/APAP group. Participants in tramadol/APAP group will receive celecoxib 200 milligram (mg) and fixed dose combination of tramadol (37.5 mg)/APAP (325 mg) as add on therapy, while the participants in non-tramadol/APAP group will receive celecoxib 200 mg only. The total duration of the study will be 4 weeks. The participants in both the groups will be given celecoxib 200 mg once daily for 4 weeks. In addition, the participants in the tramadol/APAP group will be given add-on tramadol/APAP doses 3 times a day for 4 weeks. Participants will be asked to return for follow-up at Weeks 2 and 4. Efficacy will be assessed using 100 millimeter (mm) Visual Analog Scale (VAS) while QOL will be assessed using the Oswestry Disability Index (ODI). Participant safety will be monitored throughout the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

473

Conditions

Osteoarthritis

Interventions

Tramadol/Paracetamol (APAP)DRUG

Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.

Non-Tramadol/APAPDRUG

Celecoxib 200 mg alone once daily for 4 weeks.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with chronic osteoarthritis of knee or hip for greater than (\>) or equal to (=) 1 year (based on the American College of Rheumatology (ACR) diagnostic criteria for osteoarthritis), who are experiencing at least moderate osteoarthritis pain (\>=50 millimeter \[mm\] in 100 mm Visual Analog Scale \[VAS\]) * On any Cyclooxygenase - 2 (COX-2) inhibitors for at least 2 weeks preceding the study * Women with childbearing potential must have negative pregnancy test * Women of child bearing potential must agree to use accepted methods of contraception * Participant has signed the written informed consent form Exclusion Criteria: * Participants taking Monoamine oxydase (MAO) inhibitors, neuroleptics or drugs for seizures * Severe hepatic impairment (the impaired ability of the liver to fulfill its role in metabolism) * On maintenance tramadol and/or paracetamol(APAP) * On sedative hypnotics, short-acting analgesics, topical medications and anesthetics, and/or muscle relaxants * Pregnant, lactating or breastfeeding participants

Locations (1)

Janssen Philippines

Paranaque City, National Capital Region, Philippines

Outcomes

Primary Outcomes

Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2

VAS is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

Time frame: Baseline and Week 2

Change From Baseline in VAS-pain Score at Week 4

VAS is a 100 mm scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

Time frame: Baseline and Week 4 Last Observation Carried Forward (LOCF)

Change From Baseline in Oswestry Disability Index (ODI) Score at Week 2

The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.

Time frame: Baseline and Week 2

Change From Baseline in ODI Score at Week 4

Time frame: Baseline and Week 4 (LOCF)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.